You are here: Industry Insights > Parkinson’s

News List

Parkinson’s disease market sales to reach $11.5 billion in 2029 europeanpharmaceuticalreview
August 12, 2021
The Parkinson’s disease market is set to triple in sales by 2029 driven by novel biologics and delivery systems, reports GlobalData.
AC Immune acquires Parkinson’s disease vaccine candidate pharmatimes
July 29, 2021
Swiss biopharma company AC Immune has announced its acquisition of a Parkinson’s disease vaccine candidate, developed by Affiris.
Ipsen and IRLAB sign $363m deal for Parkinson’s disease therapy pharmaceutical-technology
July 19, 2021
Ipsen has entered a licensing agreement with IRLAB to obtain exclusive global development and commercial rights for the latter’s investigational therapy, mesdopetam (IRL790).
FDA Authorizes Stem Cell Trials for Parkinson’s americanpharmaceuticalreview
June 23, 2021
Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II clinical trial to assess the efficacy and safety of multiple intravenous infusions of allogeneic adipose-derived mesenchymal stem cells in improving ...
AbbVie partners with Caraway on Parkinson’s therapeutics pharmaceutical-technology
June 11, 2021
AbbVie has signed an exclusive, collaboration and option agreement for the development and commercialisation of Caraway Therapeutics’ small molecule candidates to treat Parkinson’s disease and other related conditions.
Bayer subsidiary doses first patient with Parkinson’s disease cell therapy pharmatimes
June 10, 2021
German pharma company Bayer has announced that it has made progress in its ‘two-pronged’ approach to deliver cell and gene therapy candidates for the treatment of Parkinson’s disease.
Urgent need for disease-modifying drugs to arrest Parkinson’s disease progression: GlobalData expresspharma
April 12, 2021
There are diverse development strategies and trends in Parkinson’s disease (PD) treatment at present, however, only a few of them address the pressing need for a disease-modifying therapy (DMT).
Cambridge Sleep Sciences and Parkinson’s Concierge to test sleep device in Parkinson’s disease pharmatimes
March 15, 2021
Cambridge Sleep Sciences has announced a new partnership with Parkinson’s Concierge to explore the impact of sleep device technology in people living with Parkinson’s disease.
Parkinson’s UK invests £1.2m in drug design project pharmatimes
March 10, 2021
Charity organisation Parkinson’s UK has announced it will fund up to £1.2m into a one-year drug design project in partnership with the University of Sheffield.
Global anti-Parkinson’s drugs market to be worth over $5bn by 2023 europeanpharmaceuticalreview
February 25, 2021
Research suggests that despite a COVID-19 slump, the anti-Parkinson’s drugs market will recover due to rising numbers of Parkinson’s diagnoses and increasing investment in R&D.

Previous page 1 2 Next page